Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 768 matching trials from the live ClinicalTrials.gov search.

Filters: "castration-resistant" Clear all

Conditions: Metastatic Hormone Sensitive Prostate Cancer
Interventions: Enzalutamide, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 34
States / cities: Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 30 more

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: DZD2269; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: New York, New York • Pittsburgh, Pennsylvania

Conditions: Prostate Cancer
Interventions: Itraconazole 200 mg, Itraconazole 300mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 4
States / cities: Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan + 1 more

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biopsy, Bone Scan, Computed Tomography, Leuprolide Acetate, Magnetic Resonance Imaging, Survey Administration, Testosterone Cypionate; Procedure · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Prostate Cancer
Interventions: No Intervention; Other
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 20
States / cities: Homewood, Alabama • La Mesa, California • Wheat Ridge, Colorado + 17 more

Conditions: Prostate Cancer
Interventions: Metformin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: GTx-758; Drug
Lead sponsor: GTx; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: San Bernardino, California • Jeffersonville, Indiana • Albuquerque, New Mexico + 4 more

Conditions: Non-metastatic Castration-resistant Prostate Cancer
Interventions: Apalutamide, Darolutamide (BAY 1841788), Enzalutamide; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions: Tulmimetostat, Darolutamide, Abiraterone, Prednisone/Prednisolone, Androgen Deprivation Therapy (ADT); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more

Conditions: Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Interventions: Olaparib; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer Metastatic
Interventions: HB-302/HB-301 Alternating 2-Vector Therapy; Biological
Lead sponsor: Hookipa Biotech GmbH; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Duarte, California • San Marcos, California • Miami, Florida + 5 more

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions: Xaluritamig; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 12
States / cities: Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 7 more

Conditions: Prostate Cancer
Interventions: PSMA ADC; Drug
Lead sponsor: Progenics Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 36
States / cities: Birmingham, Alabama • Tucson, Arizona • Burbank, California + 32 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: AMG 340; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • Sarasota, Florida + 4 more

Conditions: Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Ipilimumab, Valemetostat; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Enzalutamide, Venetoclax; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Prostate Cancer
Interventions: RAD001, Bicalutamide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Bone Metastases, Castration-Resistant Prostate Cancer
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 6
States / cities: San Francisco, California • Evanston, Illinois • Baltimore, Maryland + 3 more

Conditions: Advanced and/or Metastatic Solid Tumours
Interventions: CB307; Drug
Lead sponsor: Crescendo Biologics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 42
States / cities: Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more

Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: abiraterone acetate, dietary intervention, pharmacological study, questionnaire administration, laboratory biomarker analysis; Drug · Dietary Supplement · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Prostate Cancer Non-Metastatic, Castration-Resistant
Interventions: Darolutamide (Nubeqa, BAY1841788), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 55
States / cities: Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 48 more

Conditions: Castration-resistant Prostate Cancer, Metastatic Breast Cancer, Uterine Leiomyoma
Interventions: LFA102; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Boston, Massachusetts • New Brunswick, New Jersey • Philadelphia, Pennsylvania + 2 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: ONCT-534; Drug
Lead sponsor: Oncternal Therapeutics, Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: San Francisco, California • Detroit, Michigan • Omaha, Nebraska + 6 more

Search by objective public record fields.

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

Metformin in Castration-Resistant Prostate Cancer

GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer

An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

RAD001 and Bicalutamide for Androgen Independent Prostate Cancer

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.